Antiplatelet treatment in stable coronary artery disease

Heart

Volumn 89, Issue 10, 2003, Pages 1273-1278

  Knight, Charles J ^a  

^a LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CALCIUM; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; IBUPROFEN; LOTRAFIBAN; MONOCLONAL ANTIBODY; ORBOFIBAN; SIBRAFIBAN; SOTALOL; THROMBOCYTE FACTOR 4; THROMBOXANE A2; TIROFIBAN; VON WILLEBRAND FACTOR; XEMILOFIBAN;

ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HEMOSTASIS; HUMAN; LIVER DYSFUNCTION; META ANALYSIS; MORBIDITY; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA;

EID: 0141455879     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.89.10.1273     Document Type: Review

References (16)

1. George JN. Platelets. Lancet 2000;355:1531-9A. Comprehensive review of platelet structure and function.
2. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206-18. An excellent review of the pharmacology and clinical use of aspirin.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71-86. The definitive antiplatelet meta-analysis involving around 135 000 patients.
4. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 1996;348:1329-39. A landmark trial of clopidogrel versus aspirin in a heterogeneous group of patients with vascular disease.
5. Juul-Möller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-5. The only large definitive trial of aspirin in stable angina. Around 2000 patients on sotalol were randomised to aspirin or placebo. A significant reduction in death/myocardial infarction was seen with aspirin.
6. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin - a systematic review. Lancet 2002;360:1037-43. Recent large meta-analysis that provides reassurance that coronary artery disease patients on ACE inhibitors can continue aspirin.
7. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-4.
8. Gaspoz J-M, Coxson PG, Goldman PA, et al. Cost-effectiveness of aspirin, clopidogrel or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346:1800-6. Interesting cost effectiveness analysis on the use of modern antiplatelet treatment in patients with coronary artery disease.
9. O'Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularisation. N Engl J Med 2000;342:1316-24.
10. Cannon CP, Mc Cabe CH, Wilcox RG, et al. Oral glycoprotein IIb-IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16). Circulation 2000;102:149-56.
11. The SYMPHONY Investigators. Comparison oF sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet 2000;355:337-45.
12. The 2nd SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 2001;103:1727-33.
13. Newby LK, Califf RM, White HD, et al. The failure of orally administered glycoprotein IIb-IIIa inhibitors to prevent recurrent cardiac events. Am J Med 2002;112:647-58. An important meta-analysis of the results of oral Gp IIb/IIIa inhibitors.
14. Cox D, Smith R, Quinn M, et al. Evidence of platelet activation during treatment with a GPIIb-IIIa antagonist in patients presenting with an acute coronary syndrome. J Am Coll Cardiol 2000;36:1514-9.
15. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb-IIIa inhibitors: recognition of a two-edged sword. Circulation 2002;106;379-85.
16. O'Connor FF, Shields DC, Fitzgerald A, et al. Genetic variation in glycoprotein IIb-IIIa (GPIIb-IIIa) as a determinant of the responses to an oral GPIIb-IIIa antagonist in patients with unstable coronary syndromes. Blood 2001;98:3256-60. Landmark study showing genetic polymorphisms can alter responses to antiplatelet treatment.